CONDUENT

Drug Monograph

Drug Name: **Thiola® EC (tiopronin) delayed-release tablet**
Drug Class: **Reducing and cystine-binding thiol drug (CBTD)**
Prepared For: MO HealthNet
Prepared By: Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Thiola EC is available in 100mg and 300mg tablets.
Manufacturer:	Mission Pharmacal Company, San Antonio, TX 78230
Indications:	Thiola EC is used in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone.
Costs:	$28.20 per tablet of Thiola EC 100mg and $84.62 per tablet of Thiola EC 300mg. Wholesale Acquisition Cost
Summary of Findings:	The MO Healthnet Division recommends prior authorization status for this product.
Status Recommendation:	☐ Fiscal Edit ☐ PDL ☐ Open Access ☒ Prior Authorization (PA) Required
Type of PA Criteria:	☒ Appropriate Indications ☐ No PA Required ☐ Non-Preferred ☐ Preferred

Prepared By: Jennifer Anderson PharmD, BCPS
Date: September 25, 2019

© 2019 Conduent Business Services, LLC All Rights Reserved.